<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143805</url>
  </required_header>
  <id_info>
    <org_study_id>A3921077</org_study_id>
    <nct_id>NCT01143805</nct_id>
  </id_info>
  <brief_title>A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form</brief_title>
  <official_title>A Phase 1, Open Label, Single Dose, Randomized, Cross Over Study To Estimate The Absolute Oral Bioavailability Of CP-690,550 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, a 10 mg dose of CP-690,550 will be given to study subjects on two separate
      occasions by two different routes of administration: One time by mouth in tablet form and one
      time by vein (intravenous form). The amount of CP-690,550 available in the blood following
      administration by vein will be measured and is expected to reflect the maximum amount
      possible for the 10 mg CP-690,550 dose. The amount of CP-690,550 that is achieved in the
      blood following oral tablet administration will also be measured and compared to that
      achieved following administration by vein in order to estimate how much of the maximum amount
      possible is actually absorbed into the blood following administration by mouth as a tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To estimate the absolute bioavailability of a 10 mg oral dose of tasocitinib (CP-690,550)
      compared to a 10 mg intravenous dose of tasocitinib (CP-690,550) in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf of tasocitinib (CP 690,550)</measure>
    <time_frame>PK blood samples out to 12 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast, Cmax, Tmax, and tÂ½, CL (IV dose only) and Vss (IV dose only) of tasocitinib (CP 690,550).</measure>
    <time_frame>PK blood samples out to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory tests: hematology, chemistry, urine testing</measure>
    <time_frame>Safety Laboratory testing performed out to 2 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Blood pressure, heart rate, oral temperature</measure>
    <time_frame>Vital signs out to 2 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE Reporting</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: Tasocitinib 10 mg oral tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Tasocitinib 10 mg IV Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasocitinib 10 mg oral tablet</intervention_name>
    <description>Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet</description>
    <arm_group_label>Treatment A: Tasocitinib 10 mg oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasocitinib 10 mg IV Infusion</intervention_name>
    <description>Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion</description>
    <arm_group_label>Treatment B: Tasocitinib 10 mg IV Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female (non childbearing potential)

          -  Subjects between the ages of 21 and 55 years, inclusive

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

        Exclusion Criteria:

          -  Evidence or history of any clinically significant illness, medical condition, or
             disease.

             2. Evidence or history of any clinically significant infections within the past 3
             months.

             3. Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
             cigarettes per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921077&amp;StudyName=A%20Study%20To%20Estimate%20The%20Amount%20Of%20CP-690%2C550%20%28Study%20Drug%29%20That%20Is%20Absorbed%20Into%20The%20Blood%20Of%20Healthy%20Subjects%20Following%20Oral%20A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>August 6, 2010</last_update_submitted>
  <last_update_submitted_qc>August 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Absolute Bioavailability</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

